US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
Samsung, Union Edge Closer to Deal as Strike Threat Looms 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
Elliott Targets Bio-Rad as Shares Continue to Struggle 
ALPHARETTA, Ga., Sept. 20, 2016 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that Daniel H. White, Chief Executive Officer and President, will present at the 2016 Ladenburg Thalmann Healthcare Conference on Tuesday, September 27, 2016, at 10:30 a.m. EDT in at the Sofitel Hotel in New York, NY. Mr. White will provide a Clearside overview and business update.
The presentation will be webcast live and may be accessed by visiting Clearside’s website at http://ir.clearsidebio.com. A replay of the webcast will be available for 30 business days.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly-traded, late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary suprachoroidal space microinjector to reach diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye. Clearside has a portfolio of clinical and pre-clinical programs using drug administration through the suprachoroidal space to provide a route of access to treat diseases of the back-of-the-eye such as retinal vein occlusion (RVO), uveitis, neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Clearside is currently enrolling patients in a Phase 3 clinical trial (PEACHTREE) for the treatment of patients with macular edema associated with non-infectious uveitis and has initiated IND-enabling studies for the treatment of wet AMD. Visit www.clearsidebio.com for more information.
Contacts Company: Charles Deignan Chief Financial Officer 678-270-4005 [email protected] Investors: Matthew Beck The Trout Group 646-378-2933 [email protected]
